Gilead Sciences revealed its acquisition plans for CymaBay Therapeutics, a biopharmaceutical company specialising in liver disease treatments, on February 12, 2024. Valued at approximately $4.3 billion, the deal involves Gilead purchasing CymaBay for $32.50 per share. Central to the acquisition is CymaBay’s promising drug, seladelpar, a selective peroxisome proliferator-activated receptor (PPAR) delta agonist designed for primary biliary cholangitis (PBC) treatment. With PBC affecting around 130,000 Americans, particularly women, the collaboration aims to address this unmet medical need. Seladelpar has received FDA priority review, with approval anticipated by August 14, 2024. Gilead’s Chairman and CEO, Daniel O’Day, expressed optimism about leveraging their expertise to advance seladelpar and enhance their liver disease treatment portfolio, echoing CymaBay’s commitment to improving patient outcomes.
Where Industry Meet Trends
Menu
English